Findoc-cll.in/4th_qtr_result

COLINZ LABORATORIES LIMITED
A-101, Pratik Ind. Estate, Next to Fortis Hospital, Mulund-Goregaon Link Road, Mumbai - 400 078.

AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED : 31ST MARCH 2013.

						(Rupees in '000')
			Un -audited			Audited
S. No.	Particulars		Quarter ended			Year Ended	Year Ended
			31.03.2013	31.12.2012	31.03.2012	31.03.2013	31.03.2012
PART-I
1	(a) Income from Operation
		Gross Sales	17,481	16,927	13,225	76,818	70,455
		Less: Excise Duty	1,280	1,191	1,509	5,282	4,435
	Net Sales		16,201	15,736	11,716	71,536	66,020
	(b) Other Operating Income		-	323	-	323	-
	Total Income from Operation		16,201	16,059	11,716	71,859	66,020
2	Expenditure		-	-	-	-	-
	(a)	Consumption of Materials	3,152	5,178	6,761	21,402	24,418
	(b)	Purchase of Goods Traded	1,144	942	937	5,460	3,457
	(c)	(Increase)/Decrease in stock in trade	2,434	(897)	(5,021)	1,702	(1,095)
	(d)	Staff Cost	5,566	6,709	4,610	25,748	22,545
	(e)	Depreciation	659	653	666	2,619	2,599
	(f)	Other Expenditure	2,556	2,905	3,292	12,083	11,694
	Total Expenditure		15,511	15,490	11,245	69,014	63,618
3	Profit/Loss from Operation Before Other Income (1-2)		690	569	471	2,845	2,402
4	Other Income/(Loss)		266	53	159	775	369
5	Profit/Loss before Interest & Exceptional items (3+4)		956	622	630	3,620	2,771
6	Interest		467	474	569	2,021	1,893
7	Profit/Loss after Interest but before exceptional items (5-6)		489	148	61	1,599	878
8	Exceptional items		-	-	-	-	-
9	Profit/Loss before Tax (7-8)		489	148	61	1,599	878
10	Tax Expenses (Provision for Taxation): Current tax		-	-	-	297	158
		Deffered tax	-	-	-	504	(384)

11	Net Profit/Loss after Tax (9-10)		489	148	61	798	1,104
12	Paid up Equity Share Capital (Face Value 10/- Per Share)		354,35	354,35	354,35	354,35	354,35
12	[Net of allotment money in arrears]		354,35	354,35	354,35	354,35	354,35
13	Reserves Excluding Revaluation Reserves		-	-	-	8,428	7,630
14	Earning per share (EPS) before extraordinary item (not Annualised)		-	-	-	-	-
	Basic & Diluted		-	-	-	0.17	0.24
PART-II	A. PARTICULARS OF SHAREHOLDING
1	Public Shareholding
	i)	Number of Shares	29,04,901	29,04,901	29,02,900	29,04,901	29,02,900
	ii)	Percentage of shareholding	63.55%	63.55%	63.51%	63.55%	63.51%
2	Promoters and promoter group Shareholding
	a)	Pledged/Encumbered
	i)	Number of shares	-	-	-	-	-
	ii)	Percentage of shares (as a % of the total shareholding of	-	-	-	-	-
		promoter and promoter group)
	iii)	Percentage of shares (as a% of the total share capital of the company)	-	-	-	-	-
	b)	Non-encumbered
	i)	Number of Shares	1,666,099	1,666,099	1668100	1668099	1668100
	ii)	Percentage of shares (as a% of the total shareholding	36.45%	36.45%	36.49%	36.45%	36.49%
		of promoter and promoter group)
	iii)	Percentage of shares (as a % of the total share capital of the company)	100%	100%	100%	100%	100%

	B. INVESTORS COMPLAINTS		3 Months ended 31.03.2013
	Pending at Begining of the Quarter		NIL
	Received During the Quarter		NIL
	Disposed of During the Quarter		NIL
	Remaining at the end of the Quarter		NIL

STATEMENT OF ASSETS AND LIAB ILITIES			(Rupees in '000')
Particulars			As at 31.03.2013	As at 31.03.2012
Particulars			(Audited)	(Audited)
A		EQUITY AND LIABILITIES
1		SHARE HOLDERS FUND
	a)	Share Capital	35,435	35,435
	b)	Reserves and Surplus	27,148	26,350
	Sub-Total of Shareholders Fund		62,584	61,785
2		NON CURRENT LIABILITIES
	a)	Long term borrowing	22,554	23,918
	b)	Deffered tax liability( net)	3,604	3,100
	c)	Other long term liability	147	98
	d)	Long term Provision	-	-
	Sub-Total of Non Current Liabilities		26,305	27,116
3		CURRENT LIABILITIES
	a)	Short term borrowing	-	-
	b)	Trade payable	4,014	9,217
	c)	Other current liabilities	5,652	4,057
	d)	Short term provision	-	-
	Sub-Total of Current Liabilities		9,666	13,274

		Total ( 1+2+3)	98,554	1,02,175

B		ASSETS
1		NON CURRENT ASSETS
	a)	Fixed Assets	39,761	42,361
	b)	Non current investments	3,159	3,159
	c)	Long term loans and advances	13,543	13,763
	d)	Other Non current assets	599	525
	Sub-Total of Non Current Assets		57,062	59,808
2		CURRENT ASSETS
	a)	Inventories	18,606	21,333
	b)	Trade receivable	12,717	10,843
	c)	Cash and cash equivalents	9,384	9,258
	d)	Short term loans and advances	785	933
		Sub-Total of Current Assets	41,492	42,367

		Total ( 1+2 )	98,554	1,02,175

NOTES :-

The above financial results have been taken on record at a meeting of Board of Directors held on 30-05-2013
The Company operates in single segment of manufacture of pharmaceutical formulations. Hence Accounting Standard on segment reporting is not applicable.
Previous period figures have been regrouped wherever required.